Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin. (2016)
Attributed to:
Rare disease use of clinical trial simulation for the chioce and optimization of study designs/Priomedchild Call/ER
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1208/s12248-016-9965-3
PubMed Identifier: 27631556
Publication URI: http://europepmc.org/abstract/MED/27631556
Type: Journal Article/Review
Volume: 18
Parent Publication: The AAPS journal
Issue: 6
ISSN: 1550-7416